Everything below concerns human growth hormone. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
=== Tandem Mobi === The Tandem Mobi is a smaller durable pump intended to be worn on the body or carried in clothing. It uses a 200-unit cartridge and is operated principally from a compatible smartphone app, while a physical button can deliver a preset bolus. The FDA cleared the pump in July 2023, and Tandem began its full United States launch in February 2024. The company obtained a CE mark for Mobi in 2025 and subsequently began introducing it in European markets.
As filaments grow, the pool of available G-actin molecules is managed by G-actin-binding proteins such as profilin and thymosin β-4. Profilin ensures a supply of available actin-ATP by binding to ADP-bound G-actin and promoting the exchange of ADP for ATP. Profilin's binding to the actin molecule physically blocks its addition to a filament's (−) end, but permits it to join the (+) end. Once the actin-ATP has joined the filament, profilin releases it. As formins promote the nucleation and extension of new actin filaments, they recruit profilin to the area, increasing the local concentration of actin-ATP to boost filament growth. In contrast, thymosin β-4 binds and sequesters actin-ATP, preventing it from joining a microfilament. Once an actin fiber is established, the dynamics of its growth or collapse are influenced by numerous proteins. Existing strands can be interrupted by filament cleaving proteins, such as cofilin and gelsolin. Cofilin binds along two actin-ADP molecules in a filament, forcing a movement that destabilizes the filament and causes it to break. Gelsolin inserts itself between actin molecules in a filament, disrupting the filament. After the filament breaks, gelsolin remains attached to the new (+) end, preventing it from growing, thus forcing its disassembly.
The illegal drug trade in Latin America concerns primarily the production and sale of cocaine and cannabis, including the export of these banned substances to the United States and Europe. According to United Nations Office on Drugs and Crime (UNODC), the coca cultivation is concentrated in the Andes of South America, particularly in Colombia, Peru and Bolivia; this is the world's only source region for coca. Drug consumption in Latin America remains relatively low, but cocaine in particular has increased in recent years in countries along the major smuggling routes. As of 2008, the primary pathway for drugs into the United States is through Mexico and Central America, though crackdowns on drug trafficking by the Mexican government has forced many cartels to operate routes through Guatemala and Honduras instead. This is a shift from the 1980s and early 90s, when the main smuggling route was via the Caribbean into Florida. The United States is the primary destination, but around 25 to 30% of global cocaine production travels from Latin America to Europe, typically via West Africa. The major drug trafficking organizations (drug cartels) are Mexican and Colombian, and said to generate a total of $18 to $39bn in wholesale drug proceeds per year. Mexican cartels are currently considered the "greatest organized crime threat" to the United States.
Sources: en.wikipedia.org
On taking office, Biden unveiled the U.S. Citizenship Act of 2021 and moved to dismantle several policies implemented under Donald Trump, halting construction of the Mexico–United States border wall, ending Trump's travel ban on countries with predominantly Muslim populations, and signing an executive order to reaffirm protections for DACA recipients. The Department of Homeland Security narrowed the scope of interior immigration enforcement, directing Immigration and Customs Enforcement (ICE) to prioritize national security and violent crime concerns. Illegal border crossings at the Mexico–United States border began to surge in 2021 when Biden assumed office, reaching an all-time monthly high in December 2023. Throughout 2024, crossings began to significantly decline from the December record, after Biden implemented restrictions on asylum claims from migrants who cross the border between ports of entry and urged Mexico to crack down on migrants. Deportations from October 2023 to September 2024 reached the highest level since 2014. Biden used humanitarian parole to mitigate illegal border crossings, allowing migrants to fly into the U.S. or schedule their entries through official entry points in the U.S.-Mexico border. Over a million migrants had been admitted to the U.S. under humanitarian parole as of January 2024. Between January 2021 and January 2024, the US Border Patrol confirmed more than 7.2 million illegal migrants trying to cross the Mexico–United States border, not counting gotaways. 2023 was a record year, with over 2.5 million encounters.
Atmoun in 2019 brokered a deal between Morocco's foreign intelligence agency, Direction générale des études et de la documentation (DGED) and Panzeri and his colleague Francesco Giorgi, whereby the two would each receive €50,000 a year for lobbying on behalf of Morocco. Marie Arena, head of the subcommittee on human rights comes into the Morocco scene, Atmoun invited Arena and Panzeri to Morocco in January 2022. Giorgi reported that he and Panzeri billed Atmoun for ensuring that mentions of Morocco vanished from a Parliament report on human rights violations. Later in 2022 Arena's son, Ugo Lemaire went on a trip to Morocco, paid for by a Moroccan company. Andrea Cozzolino also appears in the Morocco investigation, he was part of the committee investigating Morocco's use of spyware and was chair of the Parliament's Maghreb delegation coordinating the EU interaction with North African countries. Cozzolino and Atmoun met with Morocco's DGED in Warsaw. In September 2022, 4 Brussels MPs – David Leisterh, David Weytsman, Clémentine Barzin, and Gaëtan Van Goidsenhoven – visited the city of Laâyoune in Western Sahara. The Moroccan parliament had invited the MEPs and paid for the entire trip. Western Sahara is a disputed region, which Morocco claims to be its own. However, after the Belgium investigation opened, the MEPs' trip came under greater scrutiny.
== Anatomy == One carotid sheath is situated on each side of the neck, extending between the base of the skull superiorly and the thorax inferiorly. Superiorly, the carotid sheath encircles the margins of the carotid canal and jugular foramen. Inferiorly, it terminates at the arch of the aorta; it is continuous inferiorly with the axillary sheath at the venous angle. Its inferior end occurs at the level of the first rib and sternum inferiorly (varying between the levels of C7 and T4).
The Indian cobra (Naja naja) is a moderately venomous species, but has a rapid-acting venom. In mice, the SC LD50 for this species is 0.80 mg/kg and the average venom yield per bite is between 169 and 250 mg. Though it is responsible for many bites, only a small percentage are fatal if proper medical treatment and antivenom are given. The mortality rate for untreated bite victims can vary from case to case, depending upon the quantity of venom delivered and by the individual involved. According to one study, it is approximately 15–20% but in another study, with 1,224 bite cases, the mortality rate was only 6.5%. Estimated fatalities as a result of this species is approximately 15,000 per year, but they are responsible for an estimated 100,000–150,000 non-fatal bites per year.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.